studiocasper / iStockphoto.com

12 September 2018Americas

Victory for Mylan and Teva as appeals court affirms invalidations

Generic drug makers Mylan and Teva were afforded victory earlier this week when the US Court of Appeals for the Federal Circuit affirmed the invalidation of four patents owned by biotech company Acorda Therapeutics.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

BIO and PhRMA back Acorda in patent appeal

17 August 2017 The Biotechnology Industry Organization and the Pharmaceutical Research and Manufacturers of America, two trade groups representing US pharmaceutical companies, have backed Acorda in an appeal to the US Court of Appeals for the Federal Circuit.

Four of Acorda’s Ampyra patents invalidated

3 April 2017 A Delaware district court has invalidated four patents owned by Acorda Therapeutics after the company and Alkermes Pharma Ireland alleged that Apotex, Mylan, Roxane Laboratories and Teva infringed them.

More on this story

BIO and PhRMA back Acorda in patent appeal

17 August 2017 The Biotechnology Industry Organization and the Pharmaceutical Research and Manufacturers of America, two trade groups representing US pharmaceutical companies, have backed Acorda in an appeal to the US Court of Appeals for the Federal Circuit.

Four of Acorda’s Ampyra patents invalidated

3 April 2017 A Delaware district court has invalidated four patents owned by Acorda Therapeutics after the company and Alkermes Pharma Ireland alleged that Apotex, Mylan, Roxane Laboratories and Teva infringed them.

More on this story

BIO and PhRMA back Acorda in patent appeal

17 August 2017 The Biotechnology Industry Organization and the Pharmaceutical Research and Manufacturers of America, two trade groups representing US pharmaceutical companies, have backed Acorda in an appeal to the US Court of Appeals for the Federal Circuit.

Four of Acorda’s Ampyra patents invalidated

3 April 2017 A Delaware district court has invalidated four patents owned by Acorda Therapeutics after the company and Alkermes Pharma Ireland alleged that Apotex, Mylan, Roxane Laboratories and Teva infringed them.

More features

Broad Institute wins appeal to restore CRISPR patent in Europe

BMS faces fresh lawsuit over alleged cancer drug monopoly

WATCH: Synergy in science—navigating the landscape of pharmaceutical collaborations

Boies Schiller Flexner adds three-strong litigation team

AstraZeneca forced to clarify deal terms in row with university

Novartis loses cancer drug patent following Teva challenge at EPO

A step too far? Why Stewart’s approach is dividing opinion

WATCH: Section 112—Where has the dust settled?